Navigation

Published technology appraisals

This table lists published NICE technology appraisals. The list can be sorted by title (alphabetically), issue date and review date. You can also:

  • click the appraisal title for full details
  • click a column heading to sort the list by that column

Please note that the 'review date' is not the date when a review of it the appraisal starts, but the date NICE consults on a proposal for reviewing it. There is no guarantee that at the review date, a review will be undertaken. Appraisals which have been considered for review and where the decision has been not to carry out a review at this time are listed in static technology appraisals.

More information on the published appraisals list.

For technology appraisal guidance organised by category, use Find guidance in the main header area above.

Searching for specific technology appraisal guidance?

Published appraisals

Results 1-20 of 308

Ref Title Date Issued Review
TA95 Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (TA95) Jan 2006 TBC
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238) Dec 2011 TBC
TA194 Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194) (replaced by CG175) Jul 2010 TBC
TA147 Breast cancer (advanced & metastatic) - bevacizumab (withdrawn) (TA147) Jun 2008 TBC
TA244 Chronic obstructive pulmonary disease - roflumilast (TA244) Jan 2012 TBC
TA150 Colorectal cancer (metastatic) - cetuximab (terminated appraisal) (TA150) (replaced by TA242) Jun 2008 TBC
TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240) Dec 2011 TBC
TA102 Conduct disorder in children - parent-training/education programmes (TA102) (replaced by CG158) Jul 2006 TBC
TA231 Depression - agomelatine (terminated appraisal) (TA231) Jul 2011 TBC
TA149 Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149) Jun 2008 TBC
TA281 Gout - canakinumab (terminated appraisal) (TA281) Apr 2013 Jan 2100
TA273 Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) Jan 2013 Jan 2100
TA282 Idiopathic pulmonary fibrosis - pirfenidone (TA282) Apr 2013 TBC
TA302 Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) (TA302) Nov 2013 TBC
TA270 Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) Dec 2012 Jan 2100
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258) Jun 2012 TBC
TA148 Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148) Jun 2008 TBC
TA175 Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175) Jul 2009 TBC
TA206 Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206) Oct 2010 TBC
TA207 Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207) Oct 2010 TBC

This page was last updated: 15 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.